Industry & Business

Pharmaceutical Industry Unlikely to Avoid Harsh Brexit

 Breaking News
  • OPW Prepared For No Deal Brexit “If there is a ‘crash-out’, we will be ready. We are working 24/7,” said Maurice Buckley (pictured), Chairman of the Office of Public Works (OPW) and Vice President of Engineers Ireland, about preparations for installing infrastructure at ports and airports in the event of a ‘no deal Brexit’. “Eighteen separate construction projects are now underway [...]...
  • Irish Builders Face Cost Hikes in UK Materials The vast majority of building materials used in the Irish construction sector are either sourced in the UK or enter Ireland through international distributors in Britain and represent a major risk for the industry, according to executives at the recent National Construction Summit in Citywest, Dublin – writes John Whelan (pictured above). And a huge majority of [...]...
  • Marketing Campaign Worth €1.2 Million Unveiled by Guaranteed Irish Guaranteed Irish, the not-for-profit business membership organisation championing 600+ homegrown and international businesses in Ireland, has unveiled a new marketing campaign worth €1.2 million, aimed at showcasing its members’ success. The campaign has been launched to coincide with Guaranteed Irish Month, an annual event running throughout March that shines a spotlight on businesses in Ireland [...]...
  • Jameson Enters the Top 10 Premium Spirits Brands in the World List Jameson Irish whiskey, which is produced by Irish Distillers at Midleton Distillery in Cork, has entered the top 10 of IMPACT magazine’s annual ‘Top 100 Premium Spirits Brands Worldwide’ list for the first time ever, after increasing sales 10% to a record 7.5 million nine-litre cases in 2018. In addition, Jameson scored its 18th consecutive year [...]...
  • Growth in Demand For Waste Handling Equipment Expected Sales of waste handling and processing equipment are conservatively expected to increase by 5% to 10% annually in unit terms over the next decade, and possibly beyond, according to a study being conducted by leading Birdhill and Rathcoole-based plant and equipment distributor, McHale Plant Sales. Conscious of the growing importance of waste management, and of the [...]...

Pharmaceutical Industry Unlikely to Avoid Harsh Brexit

Pharmaceutical Industry Unlikely to Avoid Harsh Brexit
February 27
14:00 2018

By John Whelan 

International policy leaders attending the recent Bio Pharma Ambition conference in Dublin Castle were addressed by Dr Lorraine Nolan, the chief executive of Ireland’s Health Products Regulatory Authority and a member of the European Medical Agency (EMA). She stressed that continued  good working relationships with the UK regulatory MRHA, would be essential for the ‘transition period’ after the UK leaves the EU in March next year , so that the pharma and biotech companies here can transit smoothly to a new framework.

It was abundantly clear from all business leaders as well as academics and researchers at the conference that there was an enormous amount of cross collaboration between the medical, pharmaceutical and medical devices companies here and in the UK. Disrupting these links will clearly be painful and costly to all both sides of the Irish Sea.

There was also concern that the EMA‘s move to Amsterdam – now breaking down into a shambles due to delays in availability of the new offices to move into – that many will not move from the UK. Dr Nolan highlighted the major contribution of the MRHA to the work of the EMA along with the loss of capacity and expertise within the EMA – both from a review of medicines and pharma vigilance – should the UK withdraw from the European regulatory network.

Amongst the many senior industry leaders at the conference, there was strong concern that the UK was heading for a ‘disorderly withdrawal’ from the EU and its single regulatory arrangements.

Recent statements from the UK health secretary Jeremy Hunt would indicate that this concern is not misplaced. In January  he said that leaving the EU meant there would be “separate regulatory arrangements” and that he did not expect the UK to be part of  the EMA because it would entail being “subject to the European Court of Justice.”

The significance of the ‘separate regulatory arrangements’ is that this brings double testing and double the applications for approvals before medicines produced here for sale across the EU, would be saleable in the UK .

Some companies who primarily export to the UK may decide it is more efficient and less costly to move operations across the Irish Sea. When you look at the €4.8 billion of pharmaceuticals we export each year to the UK, there are undoubtedly some manufacturers who will find it imperative to shift plants over. It may be the only way they can be sure of retaining the major supply contracts they have with the British National Health Service (NHS).

One of the big concerns for the Irish Pharmaceutical Healthcare Association (IPHA) is that the supply of many commonly used medicines such as aspirins, paracetamols, strepsils; lemsips etc imported daily from the UK will be disrupted. But also a wide range of innovative rare condition drugs also come to us from the UK. The reality is that we rely on the UK for €2.9 billion of pharmaceuticals for our hospitals, chemists shop supplies and for basic ingredients for Irish life sciences industry. If these issues were not sufficient worry for the pharmacists around the country, there is also the cosmetic side of their business which imports lipsticks, face creams and body lotions from the UK. These are also under regulatory control the same as medicines and will be impacted if the UK opts for a hard Brexit  and its own regulatory regime.

Martin Shanahan, IDA chief executive put the best spin on the impending impact of a hard Brexit by pointing to the Pharma group MSD announcement of plans for a new biotech facility in Dublin, in a move that is expected to create 350 jobs. The MSD managing director Ger Brennan, in a veiled reference to potential Brexit issues, stated at the announcement: “We need to have confidence in supply.” And yes there is also the opportunity for Ireland to attract some manufacturers from the UK to set up parallel plants in Ireland to services the rest of the EU.

However, for  those in  need of medical care and especially the most vulnerable among us such as those suffering from rare conditions,  it is imperative that uncertainty is minimised throughout the Brexit negotiations and as much continuity as possible in the regulatory process between EU-27 and the UK is ensured.

About Author

admin

admin

Related Articles

New Subscriber

Subscribe Here



Advertisements





















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4